Published in Clin Exp Immunol on October 01, 1995
Chloroquine stimulates nitric oxide synthesis in murine, porcine, and human endothelial cells. J Clin Invest (1998) 0.98
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology (2015) 0.89
Immunity to malaria in Plasmodium vivax infection: a study in central China. PLoS One (2012) 0.81
Chloroquine inhibits human CD4(+) T-cell activation by AP-1 signaling modulation. Sci Rep (2017) 0.75
Triggering of the T3-Ti antigen-receptor complex results in clonal T-cell proliferation through an interleukin 2-dependent autocrine pathway. Proc Natl Acad Sci U S A (1984) 4.78
Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science (1989) 4.70
The effects of cyclosporin A on the immune system. Annu Rev Immunol (1985) 3.86
Predominantly T-cell infiltrate in rheumatoid synovial membranes. N Engl J Med (1975) 3.35
Synergy, additivism and antagonism in immunosuppression. A critical review. Clin Exp Immunol (1977) 2.89
The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum (1992) 2.68
High-affinity receptor-mediated internalization and degradation of interleukin 2 in human T cells. J Exp Med (1986) 2.37
Chloroquine and ammonium ion inhibit receptor-mediated endocytosis of mannose-glycoconjugates by macrophages: apparent inhibition of receptor recycling. Biochem Biophys Res Commun (1980) 2.13
Accessory cell independent proliferation of human T4 cells stimulated by immobilized monoclonal antibodies to CD3. J Immunol (1987) 2.03
Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. Arthritis Rheum (1988) 1.90
SUPPRESSION OF IN VITRO LYMPHOCYTE RESPONSES BY CHLOROQUINE. N Engl J Med (1965) 1.60
T cells cloned from human rheumatoid synovial membrane functionally represent the Th1 subset. Scand J Immunol (1992) 1.58
Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med (1993) 1.57
Chloroquine diphosphate in rheumatoid arthritis. A controlled trial. Ann Rheum Dis (1961) 1.43
Identification of a direct interaction between interleukin 2 and the p64 interleukin 2 receptor gamma chain. Proc Natl Acad Sci U S A (1993) 1.35
Chloroquine in rheumatoid arthritis; a double blindfold trial of treatment for one year. Ann Rheum Dis (1960) 1.33
Pharmacologic actions of 4-aminoquinoline compounds. Am J Med (1983) 1.27
Development and application of radioimmunoassays for interleukin-1 alpha and interleukin-1 beta. J Immunol Methods (1989) 1.20
Efficient propagation and cloning of human T cells in the absence of antigen by means of OKT3, interleukin 2, and antigen-presenting cells. Scand J Immunol (1988) 1.19
Inhibition of lysosomal phospholipase A and phospholipase C by chloroquine and 4,4'-bis(diethylaminoethoxy) alpha, beta-diethyldiphenylethane. J Biol Chem (1980) 1.14
Endothelial cell lysis induced by lymphokine-activated human peripheral blood mononuclear cells. Eur J Immunol (1987) 1.06
Autocrine regulation of T-lymphocyte proliferation: differential induction of IL-2 and IL-2 receptor. Immunology (1988) 1.03
Immunosuppressive potential of antimalarials. Am J Med (1983) 1.00
A controlled study of chloroquine as an antirheumatic agent. Arthritis Rheum (1958) 0.96
Cyclosporine as an immunosuppressive agent for autoimmune disease: theoretical concepts and therapeutic strategies. Transplant Proc (1988) 0.96
Internalization of human T lymphocyte receptors. Eur J Immunol (1987) 0.92
A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum (1994) 0.89
Chloroquine inhibits tumor necrosis factor production by human macrophages in vitro. J Infect Dis (1991) 0.87
Cyclosporine and chloroquine synergistically inhibit the interferon-gamma production by CD4 positive and CD8 positive synovial T cell clones derived from a patient with rheumatoid arthritis. J Rheumatol (1992) 0.85
Modulation of interleukin 2 internalization and interleukin 2-dependent cell growth by antireceptor antibodies. J Biol Chem (1991) 0.85
Interactions of chloroquine with different glycerophospholipids. Hoppe Seylers Z Physiol Chem (1980) 0.84
In vivo and in vitro action of chloroquine on surface markers of human peripheral lymphocytes. Clin Exp Immunol (1980) 0.80
The mechanism of synergistic interaction between anti-interleukin 2 receptor monoclonal antibody and cyclosporine therapy in rat recipients of organ allografts. Transplantation (1990) 0.80
Synergistic interaction of cyclosporine A with interleukin 2 receptor monoclonal antibody therapy. Transplant Proc (1988) 0.79
Receptor-mediated endocytosis of IL-2 by PHA stimulated lymphocytes. Transplant Proc (1989) 0.77
The role of receptor-ligand endocytosis and degradation in interleukin-2 signaling and T-lymphocyte proliferation. Lymphokine Cytokine Res (1991) 0.77
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum (2000) 8.64
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum (2005) 8.47
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet (1997) 6.71
Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A (1976) 6.65
Genetic influence on cytokine production and fatal meningococcal disease. Lancet (1997) 4.89
A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) (2003) 4.86
Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science (1989) 4.70
Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med (2001) 4.31
Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int (1998) 4.31
Influence of non-inherited maternal HLA antigens on occurrence of rheumatoid arthritis. Lancet (1993) 3.87
Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum (1997) 3.80
Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Annu Rev Immunol (1990) 3.55
Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis (2002) 3.53
Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum (2004) 3.38
Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum (1999) 3.08
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum (1996) 2.96
Increased risk of developing ankylosing spondylitis among first-born children. Arthritis Rheum (2000) 2.76
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol (1976) 2.64
Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene. Nucleic Acids Res (1985) 2.50
Synovial fluid T cell reactivity against 65 kD heat shock protein of mycobacteria in early chronic arthritis. Lancet (1988) 2.43
Requirement of extracellular complement and immunoglobulin for intracellular killing of micro-organisms by human monocytes. J Clin Invest (1979) 2.42
Detection of bacterial DNA in joint samples from patients with undifferentiated arthritis and reactive arthritis, using polymerase chain reaction with universal 16S ribosomal RNA primers. Arthritis Rheum (1998) 2.41
Factors predicting outcome of rheumatoid arthritis: results of a followup study. J Rheumatol (1993) 2.40
Complement in organ transplantation. Contributions to inflammation, injury, and rejection. Transplantation (1995) 2.36
Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit. EMBO J (1986) 2.35
Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet (1996) 2.30
Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum (1995) 2.25
Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum (1998) 2.24
Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis (2005) 2.23
Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis (2007) 2.22
A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) (2000) 2.19
Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A (1998) 2.18
Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum (2000) 2.14
Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum (2001) 2.11
Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles. Arthritis Rheum (2007) 2.10
Serum testosterone levels are not elevated in patients with ankylosing spondylitis. J Rheumatol (1998) 2.09
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum (2008) 2.07
Lifestyle and the risk of rheumatoid arthritis: cigarette smoking and alcohol consumption. Ann Rheum Dis (1990) 2.07
Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.07
[Arthroscopic lavage plus corticosteroids is more effective than joint aspiration plus corticosteroids in patients with arthritis of the knee]. Ned Tijdschr Geneeskd (2008) 2.05
Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter polymorphism in TNF alpha gene regulation. J Inflamm (1997) 2.05
Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta protein. Arthritis Rheum (2004) 2.05
Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum (1996) 2.03
Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol (1999) 1.99
The Leiden Early Arthritis Clinic. Clin Exp Rheumatol (2004) 1.97
Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum (1995) 1.93
Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum (2007) 1.90
Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. Arthritis Rheum (2002) 1.87
DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis (2010) 1.87
Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H. Infect Immun (1999) 1.87
The value of indirect immunofluorescence and solid phase techniques for ANCA detection. A report on the first phase of an international cooperative study on the standardization of ANCA assays. EEC/BCR Group for ANCA Assay Standardization. J Immunol Methods (1993) 1.86
Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein. Arthritis Rheum (2001) 1.84
Incidence and sources of native and prosthetic joint infection: a community based prospective survey. Ann Rheum Dis (1997) 1.83
The current status of neutrophil cytoplasmic antibodies. Clin Exp Immunol (1989) 1.78
Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods (2004) 1.78
Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J (1986) 1.78
Diagnosis and course of early-onset arthritis: results of a special early arthritis clinic compared to routine patient care. Br J Rheumatol (1998) 1.78
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Rheum (2009) 1.76
Quantification of the cell infiltrate in synovial tissue by digital image analysis. Rheumatology (Oxford) (2000) 1.76
An IL-13 promoter polymorphism associated with increased risk of allergic asthma. Genes Immun (1999) 1.75
Participation of immunoglobulins and complement components in the intracellular killing of Staphylococcus aureus and Escherichia coli by human granulocytes. Infect Immun (1981) 1.74
Long term high intensity exercise and damage of small joints in rheumatoid arthritis. Ann Rheum Dis (2004) 1.73
Should we look for osteoporosis in patients with rheumatoid arthritis? Ann Rheum Dis (1998) 1.72
Comparison of the responsiveness of the Harris Hip Score with generic measures for hip function in osteoarthritis of the hip. Ann Rheum Dis (2003) 1.71
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair. Genes Immun (2003) 1.70
Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis (1992) 1.68
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis (2012) 1.67
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis (2003) 1.64
Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol (1997) 1.63
Aggregated human immunoglobulin G stabilized by albumin: a standard for immune complex detection. J Immunol Methods (1979) 1.60
Prognostic value of Th1/Th2 ratio in rheumatoid arthritis. Lancet (1998) 1.60
Structure-function relationship of human von Willebrand factor. Blood (1987) 1.60
T cells cloned from human rheumatoid synovial membrane functionally represent the Th1 subset. Scand J Immunol (1992) 1.58
Investigation of the association of the CRTM and CRTL1 genes with radiographically evident osteoarthritis in subjects from the Rotterdam study. Arthritis Rheum (1997) 1.58
A pathogenic role for secretory IgA in IgA nephropathy. Kidney Int (2006) 1.58
Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10. Ann Rheum Dis (2002) 1.57
Neuropsychiatric systemic lupus erythematosus is associated with imbalance in interleukin 10 promoter haplotypes. Ann Rheum Dis (1999) 1.55